This paper seeks to put a spotlight on much that is wrong in the United States with cancer drug development, pricing, marketing and outcomes. Roche Pharmaceutical's cancer drug, Avastin will be used as an example to highlight these issues. Drug patents, Medicare policies, weak metrics of efficacy and ceaseless demand—allow drug manufacturers to price their oncology treatments as they choose, regardless of results, and with virtually no competition, avenue or institution that serves to lower prices in the United States. Avastin will be established as an oncology drug that is overpriced and poorly evaluated based on its effectiveness. Facts, opinions and study analytics will be offered (from industry experts, insiders, doctors and scientists) that in almost all cases show that patients treated with Avastin receive marginal benefit. Allowing Medicare to negotiate drug prices with manufacturers, reducing conflicts of interest for doctors, setting research & development investment requirements and creating more relevant clinical metrics for use in FDA approvals would help reduce the financial burden on cancer patients and taxpayers.